27 results
8-K
EX-99.1
IVVD
Invivyd Inc
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down of adintrevimab clinical trials
8-K
EX-99.1
IVVD
Invivyd Inc
9 Feb 24
Index to Consolidated Financial Statements
4:01pm
minimum purchase commitments. Certain of these agreements provide for termination rights subject to the payment of termination fees and/or wind-down
8-K
EX-99.1
IVVD
Invivyd Inc
9 Nov 23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:10pm
trial costs in 2022 due to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down
8-K
EX-99.1
6vz4id68lq1 rqwhkxsx
11 May 23
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
8-K
EX-99.1
ax51ajek97chd3jcf9l
10 Nov 22
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
4:13pm
10-K
6vc94c twghc7jp33
31 Mar 22
Annual report
8:18am
10-Q
1pzw2mb
20 Sep 21
Quarterly report
4:17pm
424B4
3f0q75bzihpzo yd5f
6 Aug 21
Prospectus supplement with pricing info
4:54pm
S-1/A
yt462 gb4
2 Aug 21
IPO registration (amended)
6:20am